Amgen through its wholly-owned subsidiary Pillartree has agreed to acquire Ireland-based biopharmaceutical firm Horizon Therapeutics for an enterprise value of around $28.3bn. The US biotechnology company will pay $116.5 per share in cash, which is a premium of around 19.7% to Horizon Therapeutics’ closing stock price of $97.29 per share on 9 December 2022. Horizon […]
Amgen has agreed to acquire ChemoCentryx, a biopharma company engaged in developing medications for inflammatory and autoimmune diseases and cancer, in an all-cash deal worth around $3.7 billion. Based in California, ChemoCentryx is listed on NASDAQ. As per the terms of the deal, its shareholders will be offered $52 per share. Through the deal, Amgen […]
Amgen acquisition of Five Prime Therapeutics : Amgen has agreed to acquire Five Prime Therapeutics, a clinical-stage biotech company, for about $1.9 billion, to add a phase 3 ready gastric cancer candidate called bemarituzumab. Based in California, Five Prime Therapeutics is engaged in developing immuno-oncology and targeted cancer therapies. Amgen will acquire the biotech company […]
US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per the latest pharma acquisition news. The Beijing-based BeiGene is a research-based, oncology-focused biotechnology company, which is engaged in developing molecularly targeted and immuno-oncology drug candidates for cancer treatment. The transaction […]